UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 01/08/2007
Myriad Genetics, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-26642
Delaware | | 87-0494517 |
(State or other jurisdiction of | | (IRS Employer |
incorporation) | | Identification No.) |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices, including zip code)
801-584-3600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Information to be included in the report
Item 8.01. Other Events
On January 8, 2007, Myriad Genetics, Inc. announced the results of its multi-center, double-blind, placebo-controlled human clinical trial of MPC-7869 (R-flurbiprofen) in prostate cancer. The information in the press release dated January 8, 2007 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.1 hereto.
Item 9.01. Financial Statements and Exhibits
99.1 The Registrant's press release dated January 8, 2007 concerning MPC-7869 (R-flurbiprofen).
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | Myriad Genetics, Inc. |
| |
| |
| Date: January 08, 2007 | | | | By: | | /s/ Peter D. Meldrum
|
| | | | | | | | | Peter D. Meldrum |
| | | | | | | | | President and Chief Executive Officer |
| |
| |
Exhibit Index
Exhibit No.
| | Description
|
| EX-99.1 | | The Registrant's press release dated January 8, 2007 concerning MPC-7869 (R-flurbiprofen). |
